AUTHOREA
Log in Sign Up Browse Preprints

loading page

A case of chronic myelogenous leukemia with the T315I mutation who progressed to myeloid blast phase and was successfully treated with asciminib
  • Sarah Tomassetti,
  • Jennifer Lee,
  • Xin Qing
Sarah Tomassetti
Harbor-UCLA Medical Center

Corresponding Author:[email protected]

Author Profile
Jennifer Lee
Harbor-UCLA Medical Center
Author Profile
Xin Qing
Harbor-UCLA Medical Center
Author Profile

Abstract

Patients with chronic myelogenous leukemia (CML) harboring the T315I mutation who progress to blast phase CML while on ponatinib may be successfully treated with asciminib monotherapy following induction therapy with cytotoxic chemotherapy.

Peer review status:Published

14 Jun 2022Submitted to Clinical Case Reports
Show details
Hide details
16 Jun 2022Submission Checks Completed
16 Jun 2022Assigned to Editor
06 Jul 2022Reviewer(s) Assigned
26 Jul 2022Review(s) Completed, Editorial Evaluation Pending
21 Aug 2022Editorial Decision: Revise Minor
02 Sep 20221st Revision Received
03 Sep 2022Submission Checks Completed
03 Sep 2022Assigned to Editor
03 Sep 2022Review(s) Completed, Editorial Evaluation Pending
08 Oct 2022Editorial Decision: Accept
Nov 2022Published in Clinical Case Reports volume 10 issue 11. 10.1002/ccr3.6478